Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CM326 in Patients With Chronic Rhinosinusitis With Nasal Polyps
NCT05324137Phase 2Completed
- Sponsor
- Keymed Biosciences
- Start
- Jul 2022
- Primary completion
- Mar 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of CM326 in chronic rhinosinusitis with nasal polyps (CRSwNP) (5 arms), sponsored by Keymed Biosciences. Primary endpoints: Incidence of AEs at Week 64 and Changes from baseline of nasal polyp score (NPS) in eosinophilic chronic rhinosinusitis with nasal polyps (CRSwNP) at Week 16. Started Jul 2022; status: completed.
02
Drugs
CM326
03
Conditions
chronic rhinosinusitis with nasal polyps (CRSwNP)
Beyond the preview
Go deeper on NCT05324137.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05324137.